Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Xspray Pharma AB ( (SE:XSPRAY) ) just unveiled an announcement.
Xspray Pharma AB announced a change in its share capital structure following the completion of a rights issue and an expanded over-allotment issue that was upsized due to strong investor demand. The total number of outstanding shares and votes has increased by 5,674,234 to 47,416,574, raising the company’s share capital by a corresponding SEK 5,674,234 and signaling solid market appetite for funding its oncology-focused pipeline and ongoing FDA review processes.
The successful capital raise strengthens Xspray Pharma’s financial base as it advances multiple product candidates built on its HyNap technology, including lead drugs Dasynoc and Nilopki now under regulatory review. By bolstering its balance sheet through an oversubscribed equity issuance, the company appears better positioned to pursue its ambition of leadership in improved protein kinase inhibitor therapies, which may benefit shareholders through enhanced development capacity and potential future commercialization opportunities.
More about Xspray Pharma AB
Xspray Pharma AB is a Swedish pharmaceutical company focused on developing improved versions of marketed protein kinase inhibitors, a major segment of the oncology market characterized by high drug prices. Using its patent-protected HyNap technology platform, the company is advancing several clinical-stage product candidates, including lead drug Dasynoc, Nilopki, XS008-axitinib and XS025-cabozantinib, with the goal of becoming a market leader in optimized PKI-based cancer treatments.
Dasynoc, an amorphous form of dasatinib, is designed to deliver bioequivalent exposure at a 30% lower dose due to better solubility and offers compatibility with proton pump inhibitors, which are frequently prescribed to CML and ALL patients. Both Dasynoc and Nilopki, an optimized version of Tasigna, are currently under review by the U.S. Food and Drug Administration, while the company’s shares trade on Nasdaq Stockholm under the ticker XSPRAY, reflecting its positioning as an oncology-focused innovator in the capital markets.
Average Trading Volume: 51,641
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.24B
For detailed information about XSPRAY stock, go to TipRanks’ Stock Analysis page.